Currently Viewing:
European Society of Cardiology (ESC) 2017
Dr Christi Deaton on the Most Important Steps for Cardiovascular Prevention
November 12, 2017
Dr John Rumsfeld: We're Just at the Beginning of the Digital Health Transformation
November 09, 2017
Dr Jeanette Stingone on Environmental Factors That Impact Public Health
November 07, 2017
Christi Deaton: Challenges of Motivating Patients to Participate in CVD Prevention Strategies
November 04, 2017
Dr John Rumsfeld on the Digital Transformation of Cardiovascular Medicine
October 24, 2017
Dr Deepak Bhatt on the Impact of the COMPASS Trial on Standard of Care
October 19, 2017
Dr Jeanette Stingone: Air Pollution Is an Issue Everywhere in the US
October 12, 2017
Dr John Rumsfeld Outlines ACC's Main Goals for the Future of Cardiology
October 07, 2017
Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments
October 03, 2017
Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol
October 01, 2017
Dr John Eikelboom on the COMPASS Trial Findings
September 28, 2017
Currently Reading
Dr John Eikelboom on the Surprising Results of the COMPASS Trial
September 15, 2017
Dr Christi Deaton: Ask Cardiac Patients About Their Diet and Exercise
September 12, 2017
Dr Steven Nissen on Which Patients Should Be Treated With PCSK9 Inhibitors
September 11, 2017
Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution
September 07, 2017
Dr Christi Deaton on Promoting Better Self-Management for Patients With CVD
August 29, 2017
Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD
August 29, 2017
Comorbidities in Patients With Heart Failure: Treating the Whole Patient
August 29, 2017
Dr Simon Gibbs on Daily Management of Patients With Pulmonary Hypertension
August 28, 2017

Dr John Eikelboom on the Surprising Results of the COMPASS Trial

John Eikelboom, MD, of McMaster University discusses the 3 outcomes of the COMPASS trial that address the main concerns of patients.


John Eikelboom, MD, of McMaster University discusses the 3 outcomes of the COMPASS trial that address the main concerns of patients.

Transcript (slightly modified)

What specific data set from the COMPASS trial were you most surprised with?

The COMPASS trial results are, of course, exciting, but also some outstanding results, some results that really heighten the imagination. What are the 3 outcomes that my patient says “I just absolutely do not want these outcomes”? Well the first that comes to mind is stroke—42% risk reduction in stroke. Unexpected and I think real, although, there is a play of chance and maybe it was a little bit bigger of a treatment effect than we’d anticipated, but who could imagine that we would reduce the risk of ischemic stroke by almost 50%. 

The second outcome that my patients fear is an amputation. I don’t think there’s anybody in the world who does not fear the prospect of amputation. In the COMPASS trial, we saw a reduction by half, by more than half, in the need for amputation.

The third outcome I think my patients don’t want is, by and large, they don’t want to die. It’s very hard to show mortality benefit in any antithrombotic population during long term treatment, but plucking these people of the street with chronic, stable cardiovascular disease and mortality reduction, I would say they are my 3 highlights.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!